Answers are grounded in this paper and cite their sources.
Introduction Liver cancer is the sixth leading cause of cancer and the third leading cause of cancer-related deaths globally (GLOBOCAN). Hepatocellular carcinoma (HCC) represents about 90% of primary liver cancers and constitutes a major global health problem.[1] The number of new cases in China accounted for 46.6% of the global liver cancer cases, and 47.1% of the global liver cancer deaths occurred in China.[2] In China, the annual incidence of liver cancer is about 370,000, ranking fourth in the incidence of malignant tumors in China (26.92/100,000), and the annual number of deaths is about 326,000, ranking second in the mortality rate of malignant tumors in China (23.72/100,000).[3] Although some progress has been made in the prevention and control of liver cancer in China in recent years with the progress of vaccination, antiviral therapy, and early screening technology, the morbidity and mortality rates remain high, especially in rural areas and high-risk groups. The early symptoms of liver cancer are not obvious, and the diagnosis often occurs at an advanced stage, which seriously affects the survival rate of patients. The overall 5-year survival rate is less than 15%.[4] To address this challenge, it is very important to develop a highly effective, safe, affordable, and accessible treatment strategy for liver cancer. 2. Current status and progress of hepatocellular carcinoma The treatment of HCC selects different therapies according to the disease stage. The disease stage is mainly based on the BCLC (Barcelona Clinic Liver Cancer) staging system, that is, the comprehensive stage based on patient ECOG physical fitness score, Child-Pugh liver function rating, and tumor status.[5] Approximately 30% of HCC cases are diagnosed at early stages (BCLC 0 or A), and primary treatments include surgical resection, ablation, and liver transplantation. However, the 5-year recurrence rate is still as high as 70%.[6] Transarterial chemoembolization (TACE) is the standard treatment for unresectable, nonmetastatic HCC (stage BCLC B, Child-Pugh A/B, ECOG fitness score 0–1).[7] However, the median progression-free survival (mPFS) remains poor (approximately 7–8 months), and recurrence is common.[8] For patients who did not respond to TACE during the first two procedures, response rates to subsequent TACE are low and TACE procedures can cause deterioration of liver function, limiting eligibility for systemic therapies after TACE.[9] For patients with advanced (stage BCLC C, portal invasion, extrahepatic metastasis, ECOG physical score 0–2, Child-Pugh A/B) liver cancer, multitarget tyrosine kinase inhibitors sorafenib, lenvatinib, and donafenib were approved for first-line treatment of hepatocellular carcinoma, and rivoceranib (apatinib), regorafenib, and cabozantinib were approved for second-line treatment of hepatocellular carcinoma.[10] In recent years, with the continuous development of molecular biology, a large number of new drugs have greatly expanded the treatment options for intermediate and advanced HCC. Immune checkpoint inhibitors (ICIs) combined with antiangiogenesis-targeted drugs (AATDs), such as IMbrave150, ORIENT32, and CARES-310 studies, can significantly improve the prognosis of advanced liver cancer. The objective response rate (ORR) for advanced HCC was 20.5%–36% (mRECIST standard), median progression-free (mPFS) was 4.6–8.6 months, and median overall survival (mOS) was 19–22.1 months.[11–13] For example, 543 patients with unresectable or metastatic hepatocellular carcinoma who had not previously received any systemic treatment were randomly assigned (1:1) to receive either camrelizumab plus apatinib or sorafenib in the CARES-310 study. The results of camrelizumab-rivoceranib versus sorafenib showed that the ORR was 25.4% vs 5.9% (RECIST v1.1 standard), and 33.1% vs 10% (mRECIST standard), respectively. The mPFS was 5.6 vs 3.7 months, the disease control rate (DCR) was 78.3% vs 56.1% (mRECIST standard), and mOS was 22.1 months vs 15.2 months. All the differences were statistically significant.[14] However, the overall ORR and mPFS are still low, which also stimulates researchers' efforts to explore the systemic therapy combined with local therapy such as interventional, radiation, and ablation therapies, and also marks the treatment of HCC from the 2.0 era of ICIs combined with AATD into the 3.0 era of local therapy plus immune-targeted therapy.[14] Oxaliplatin-based systemic chemotherapy, such as FOLFOX4 regimen, is the first line for the treatment of advanced liver cancer in China,[15] but it is not widely used clinically due to limited benefits. In recent years, Chinese scholars have applied mFOLFOX to hepatic artery infusion chemotherapy (HAIC) and achieved good results. Zhao Ming et al.[16] first reported that the mFOLFOX regimen was used in HAIC for advanced liver cancer, with a DCR of 79.6%, which was significantly better than sorafenib monotherapy. The mechanism lies in the double blood supply of the portal vein and hepatic artery of the liver, and liver cancer is mainly supplied by the hepatic artery. Through the hepatic artery perfusion, the high concentration of chemotherapy drugs is directly and continuously infused into the tumor blood supply artery, which can significantly improve the drug concentration in the liver cancer tissue.[17] The results of the prospective study by He et al.[18] showed that the objective response rate, conversion rate, and safety of mFOLFOX-HAIC were significantly better than that of TACE in patients with unresectable liver cancer. For patients with HCC whose tumor load is concentrated in the liver or have portal vein cancer thrombus, HAIC therapy has a higher tumor remission rate. In some patients, the tumor load is significantly decreased, or the large vessel cancer thrombus regresses significantly after HAIC therapy, thus providing the opportunity for transformation resection or ablation therapy.[10] At the same time, TACE and HAIC have different mechanisms of action from ICIs and AATDs, and the triple-therapy scheme of TACE/mFOLFOX-HAIC combined with immune-targeted therapy has attracted the attention of many scholars and has been applied in clinical practice. In the past 2 years, many retrospective and prospective studies have announced that the triple-treatment regimen can enhance the efficacy and further improve the prognosis of advanced liver cancer, with ORR of 52.9%–88.6% (mRECIST standard), DCR of 85.3%–97.1%, and 6-month PFS of 66.7%–85%.[6,13,19–27] The results of two phase 3 clinical studies of TACE combined with immune-targeted therapy were also published at Lancet this year. The patients enrolled in the EMERALD-1 study were unresectable hepatocellular carcinoma with 83% stages BCLC A and B, and the Child-Pugh score was A-B7, which showed that duvalizumab + TACE + bevacizumab showed a statistical and clinical significance in improving PFS. The median progression-free survival was 15.0 months (95% CI, 11.1–18.9) with durvalumab plus bevacizumab and TACE, 10.0 months (95% CI, 9.0–12.7) with durvalumab and TACE, and 8.2 months (95% CI, 6.9–11.1) with placebo and TACE.[28] The patients enrolled in the LEAP-012 study had unresectable hepatocellular carcinoma without extrahepatic metastases, stages BCLC A and B, and Child-Pugh score A. TACE plus lenvatinib plus pembrolizumab, compared with TACE plus placebo, showed a significant and clinically meaningful improvement in progression-free survival (14.6 vs 10.0 months), and an improvement in ORR (47% vs 33%).[29] Because of the improvement in ORR, DCR, and PFS, the triple-therapy regimen has been widely used in the clinical practice of intermediate and advanced HCC in China, especially when the tumor has a surgical transformation opportunity, and has become the current preferred scheme.[30]Table 1 shows efficacy data of first-line ICIs plus AATDs combined with hepatic artery chemotherapy in advanced HCC. Table 1 - Efficacy data of first-line ICIs plus AATDs combined with hepatic artery chemotherapy in advanced HCC First-line scheme Research name Phase Sample size (n) mPFS (mo) PFS rate (%) mOS (mo) OS rate (%) Carilizumab + apatinib[13] CARES-310 III 272 5.6 6-mo: 48.212-mo: 29.8 22.1 12-mo: 76.518-mo: 60.9 Altylinizumab + bevacizumab[6,11] IMbrave150 III 336 6.90 6-mo: 54.5 19.2 6-mo: 84.812-mo: 67.2 Papabolizumab + lunvatinib[8] LEAP-002 III 395 8.2 12-mo: 34.124-mo: 16.7 21.2 24-mo: 43.730-mo: 39.2 Alentilizumab + caporotinib[31] COSMIC-312 III 370 6.8 6-mo: 54.512-mo: 28.5 15.4 6-mo: 81.412-mo: 61.8 FOLFOX-HAIC + triplizumab + levavatinib[20] LTHAIC II 36 10.4 6-mo: 80.6 NR — Carilizumab + apatinib + HAIC (FOLFOX)[21] TRIPLET II 35 10.38 6-mo: 85.012-mo: 34.218-mo: 22.8 NR 6-y: 94.312-y: 87.424-y: 65.0 The PD-1 inhibitor + levavatinib + HAIC[22] HPL R 70 8.8 3-mo: 86.76-mo: 68.912-mo: 43.2 15.9 3-mo: 97.86-mo: 86.712-mo: 67.4 HAIC + PD-1 antibody[23] HAICAP R 81 10.0 3-mo: 84.66-mo: 66.812-mo: 41.8 18.0 6-mo: 97.512-mo: 80.418-mo: 55.1 Altylinizumab + bevacizumab + HAIC (FOLFOX)[24] — R 52 10.6 6-mo: 84.612-mo: 35.6 NR 6-mo: 96.212-mo: 86.5 AATDs, antiangiogenic targeted drugs; HAIC, hepatic artery infusion chemotherapy; HCC, hepatocellular carcinoma; ICIs, immune checkpoint inhibitors; R, retrospective. 3. Our novel approach Several studies have shown that oxaliplatin and fluorouracil can induce immunogenic cell death in tumor cells and induce antitumor immune response in the body.[32] Animal trials showed that oxaliplatin regulates the liver tumor microenvironment and shows synergistic effects with ICI therapy.[33] It has been observed in gastrointestinal tumors and lung cancer that systemic chemotherapy combined with immune-targeted therapy can have a significantly better antitumor effect than immune-targeted therapy alone. For example, according to KEYNOTE-811 study,[34] pabolizumab combined with trastuzumab and chemotherapy can increase the ORR of HER 2-positive advanced gastric cancer from 51.9% to 74.4%. In the clinical treatment of advanced HCC, we found that treatment effect was significantly improved when the immune-targeted therapy was recombined with mFOLFOX intravenous infusion chemotherapy (Venous Infusion Chemotherapy, VIC). Therefore, our group conducted a phase I study: an open, single-arm, exploratory clinical study of an intravenous mFOLFOX7 regimen combined with carrelizumab and apatinib for the first-line treatment of stage CNLC III HCC (NCT05412589). Thirty-five patients with HCC received study treatment and were evaluated for efficacy, including 33 males and 2 females. The median age was 48 years (33–74 years). Twenty (57.1%) had an initial maximum diameter of greater than or equal to 10 cm, and 12 (34.3%) had HCC with portal trunk plugs (Vp 4). By June 2024, the median follow-up time was 14.3 months (6.0–25.6 months). The confirmed ORR was 60.0% (95% CI, 42.9–77.1) per RECIST 1.1, whereas it was 68.6% (95% CI, 52.4–84.8) per mRECIST. Twenty-two patients (62.9%) underwent the operation successfully, and 8 patients (38.1%) reached a pathological complete response. In particular, the 12 VP4 patients were equally effective, with ORR of 66.7% (RECIST 1.1 standard) and 83.3% (mRECIST standard). The disease control rate was 97.1% (95% CI, 91.3–102.9) per RECIST 1.1 or mRECIST. The surgical conversion rate was 62.9% (22/35), whereas median PFS based on RECIST v1.1 was 15.5 months, and median OS was not yet reached. The incidence of treatment-related AEs was 100% (35/35), and grade 3 TEAEs were observed in 57.1% (20/35). All patients improved after symptomatic treatment. The most common adverse events (AEs) were increased glutamate transaminase (48.6%), decreased platelet count (48.6%), and increased aspartate aminotransferase (45.71%). Of the 22 patients, 21 patients had R0 resection, 8 patients (36.4%) had pathological complete response (pCR), microvascular invasion (MVI) was positive in 5 (22.7%). The median follow-up was 12.0 months (1.0–21.5 months). Among the 4 patients with postoperative recurrence, 1 died, and 3 received other treatment. Eighteen had tumor-free survival; 14 had ended the treatment period and entered the follow-up observation period.[35,36] To further understand the intuitive differences in the combination of immunotargeting with HAIC, VIC, or TACE, we compared several phase II clinical studies in combination with HAIC or TACE, on the basis of carrelizumab plus apatinib treatment, as shown in Table 2. Table 2 - Lateral comparison of four treatment strategies based on carilizumab plus apatini for advanced HCC Classification mFOLFOX-HAIC + carilizumab + apatinib[21] (TRIPLET) mFOLFOX-VIC + carilizumab + apatinib[35,36] (VIC-TRIPLET) TACE + carilizumab + apatinib[25] (CARES-005) Carilizumab + apatinib[13] (CARES-310) BCLC stages C: 100% C: 100% A: 14%; B: 44%; C: 42% B: 14%; C: 86% Child-Pugh A A (60%), B (40%) A A VP4 type 22.9% (8/35) 34.3% (12/35) 27% (contains VP327/100) Not included in Sample size (n) 35 35 100 272 ORR 77.1% (RECISTv1.1)88.6% (mRECIST)) 60.0% (RECIST v1.1)68.6% (mRECIST) 65.% (RECISTv1.1)61% (mRECIST) 25.4% (RECIST v1.1)33.1% (mRECIST) DCR 97.1% 97.1% 87% 78.3% CR/pCR 11.4% (mRECIST) 31.4% (mRECIST + PCR) 16% (mRECIST) 5.1% (mRECIST) 6-mo PFSR 85.0% 93.6% (95% CI, 76.8–98.4) 70.8% 48.2% (95% CI, 41.9–54.3) mPFS (mo) 10.38 15.5 8.8 5.6 1-y OS rate 85.4% 76.6% 74.5% 76.5 Surgery rate 17.1% (6/35) 62.9% (22/35) — — Grade 3–4 AEs 65.38% 57.1% 76.6% 80.90% TRIPLET study: mFOLFOX-hepatic artery infusion chemotherapy + apatinib (250 mg, qd) + carilizumab (200 mg, q3w); VIC-TRIPLET study: mFOLFOX-venous infusion chemotherapy + apatinib (250 mg, qd) + carilizumab (200 mg, q3w); CARES-005 study: cTACE + carilizumab (200 mg, iv, q3w) + apatinib (250 mg, po, qd); CARES-310 study: carilizumab (200 mg, iv, q2w) + apatinib (250 mg, po, qd).AEs, adverse events; CR, complete response; HCC, hepatocellular carcinoma; mPFS, median progression-free; ORR, objective response rate; OS, overall survival; pCR, pathological complete response; PFSR, progression-free rate. According to Table 2, when carrelizumab plus apatinib were combined with TACE or FOLFOX-HAIC or mFOLFOX-VIC, the triple-treatment strategy consistently improved mPFS and ORR, similar to previous immune-targeted therapy with HAIC or TACE. At the same time, the VIC-TRIPLET study showed some advantages in median PFS and subsequent surgical treatment, although the baseline characteristics were poor (some Child-Pugh B patients were enrolled, and the proportion of VP4 type HCC patients was relatively high). The use of TACE/HAIC is restricted due to the presence of preexisting liver diseases (such as cirrhosis, viral hepatitis, alcohol-induced liver disease, and NASH) in liver cancer patients. Although HAIC can exert the first-pass effect on the liver and reduce the systemic toxicity caused by anticancer drugs, the damage to the liver was significantly worse than systemic chemotherapy, which was unfavorable for the surgical transformation and long-term survival. As shown in a retrospective cohort study,[37] the proportion of patients with impaired ICG clearance (ICG-R15 > 0.10) was significantly increased after FOLFOX-HAIC (from 10.8% to 34.6%, p < 0.001). Compared with HAIC, systemic chemotherapy has the following advantages: noninvasive operation, no technical barriers, easy promotion, high accessibility, high reproducibility and homogeneity, high comfort level of the patient, low operation cost, and more, which can significantly reduce the burden of patients and medical insurance. Therefore, immune-targeted therapy combined with mFOLFOX systemic chemotherapy deserves further investigation. We designed a phase III multicenter clinical study: mFOLFOX-systemic chemotherapy versus mFOLFOX-hepatic artery perfusion chemotherapy, combined with carlizumab and apatinib, for first-line treatment of stage BCLC C liver cancer: a non-inferiority, multicenter, randomized controlled study (NCT06172205). Findings from this study were presented as a wall poster at the 2024 ASCO meeting,[38] and the related experiment is currently in progress. 4. Expectations With the continuous advancement of drugs, the treatment of advanced liver cancer has entered the 3.0 era of immune-targeted therapy. The triple-therapy regimen, combining TACE/HAIC with immune-targeted therapy, has significantly advanced liver cancer treatment, markedly improving outcomes. However, in the era of immune-targeted therapy for liver cancer, it may be time to redefine the role of systemic chemotherapy. The correction of the systemic immune status of liver cancer patients and the improvement of the tumor microenvironment may be more important than the direct killing of tumor cells by chemotherapy drugs. It is expected that there will be more studies in the treatment of intermediate and advanced liver cancer in the future to explore the optimization regimen of chemotherapy drugs in comprehensive treatment, in order to achieve more efficient, safe, and economical goals.
No takes yet. Share an insight, caveat, or question.
Linhui Peng (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: